Investigating treatments and prevention strategies for HIV in children and adolescents
Official title: IMPAACT RELATED PROTOCOLS FOR THE RESEARCH ON TREATMENT, PREVENTION, DIAGNOSIS AND EPIDEMIOLOGY OF HIV INFECTIONS
Funded at Westat, INC. · NIH-10369859 · Data updated 2026-11-12
This study is looking for better ways to treat HIV and its effects in babies, kids, teens, and pregnant women, so they can live healthier lives, especially by preventing the virus from passing from mothers to their children.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Westat, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2021 |
| Award (this year) | $2,486,704 |
| NIH project number | 275201800001I-0-759402100001-1 |
| Project ID | NIH-10369859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include infants, children, and adolescents living with HIV or at risk of HIV infection, as well as pregnant women.
✕Less likely to help
Patients who are not affected by HIV or are outside the age range of 0-21 years may not benefit from this research.
What this research studies
This research focuses on developing and evaluating therapies for HIV infection and its related complications in infants, children, adolescents, and pregnant women. The IMPAACT Network conducts clinical trials to assess the effectiveness of various interventions, including those aimed at preventing mother-to-child transmission of HIV. By collaborating with a wide range of institutions and experts, the research aims to improve treatment protocols and enhance the overall health outcomes for young patients affected by HIV. The trials are designed to adapt to new scientific findings and community needs, ensuring that the most relevant and effective strategies are explored.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and preventive measures for HIV in young populations, significantly enhancing their quality of life.
How similar studies have gone: Previous research within the IMPAACT Network has shown success in developing effective interventions for HIV treatment and prevention in similar populations.
Where this research is happening
-
Westat, INC.
Rockville, United States Active
Researchers
- Principal investigator: Driver, Barbara — Westat, INC.
- Study coordinator: Driver, Barbara
Related research
Other NIH-funded projects on the same topics.
-
Camino HIV Prevention and Care Study
This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use
In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
-
Screen2Prevent: HIV screening for teens and young adults in emergency departments
The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.
-
Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART
This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.